AstraZeneca has licensed a NASH candidate from Ionis. The Big Pharma is paying $30 million upfront to pick up the rights to the program and take it into the clinic. Ionis advanced the asset through ...
AstraZeneca has bought rights to an experimental antisense therapy from Ionis Pharmaceuticals, in a deal that could be worth more than $300 million AstraZeneca has bought rights to an experimental ...
Almost a year after giving up on a non-alcoholic steatohepatitis (NASH) drug licensed from Regulus, AstraZeneca has taken another tack, buying an Ionis candidate in a deal valued at up to $330m. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results